Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 11:39 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 913–936 of 6,194 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Medication Group Clear all

Conditions: Cardiopulmonary Arrest, Respiratory Arrest
Interventions: Etomidate, Ketamine, Emergency Endotracheal Intubation, Mechanical Ventilation; Drug · Procedure · Device
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 801 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Depressive Disorder, Major
Interventions: Vortioxetine, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 462 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 39
States / cities: Anaheim, California • Cerritos, California • Costa Mesa, California + 36 more

Conditions: Opioid Abuse
Interventions: Overdose Notification; Behavioral
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Cancer
Interventions: Bromelain and Comosain; Biological
Lead sponsor: Oeyama-Moto Cancer Research Foundation; Other
Eligibility: 18 Years to 85 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: West Covina, California

Conditions: Model of Care for Hospitalized Older Adults
Interventions: Not listed
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 75 Years and older
Enrollment: 346 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: New York, New York

Conditions: Suicide Risk, Major Depressive Disorder (MDD)
Interventions: Suvorexant (dual orexin receptor antagonist); Drug
Lead sponsor: Marianne Goodman; Other
Eligibility: 18 Years to 70 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Depressive Disorder
Interventions: PEER Interactive Report; Device
Lead sponsor: MYnd Analytics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 1,922 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2022
U.S. locations: 2
States / cities: Bethesda, Maryland • Fort Belvoir, Virginia

Conditions: Hyperlipidemia
Interventions: SLx-4090, Placebo, Statin; Drug · Other
Lead sponsor: Response Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 133 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 19
States / cities: Birmingham, Alabama • Tempe, Arizona • Tucson, Arizona + 14 more

Conditions: Influenza Immunisation, Healthy Volunteers
Interventions: Quadrivalent RIV with H3 strain 1, Quadrivalent RIV with H3 strain 1 and adjuvant, Quadrivalent RIV with H3 strain 2, Quadrivalent RIV with H3 strain 2 and adjuvant, Quadrivalent RIV with 2018-2019 NH H3 strain, Quadrivalent RIV with 2018-2019 NH H3 strain and adjuvant; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 210 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 5
States / cities: San Diego, California • Melbourne, Florida • Orlando, Florida + 2 more

Conditions: Rheumatoid Arthritis
Interventions: Tocilizumab 162 mg, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 656 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 44
States / cities: Peoria, Arizona • Scottsdale, Arizona • Tucson, Arizona + 36 more

Conditions: Dry Eye Disease
Interventions: Xalatan, Travatan Z; Drug
Lead sponsor: Ophthalmic Consultants of Long Island; Other
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2011
U.S. locations: 5
States / cities: East Meadow, New York • Lynbrook, New York • Rockville Centre, New York + 2 more

Conditions: Peripheral Artery Disease (PAD)
Interventions: Ticagrelor, Comparator; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 50 Years to 130 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 10
States / cities: Daytona Beach, Florida • Jacksonville, Florida • Ocala, Florida + 7 more

Conditions: Atrial Fibrillation
Interventions: Anti Arrhythmics, Pulmonary Vein Isolation performed by Radio Frequency Catheter Ablation; Drug · Procedure
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 5
States / cities: Tucson, Arizona • The Bronx, New York • Cleveland, Ohio + 1 more

Conditions: Diabetic Macular Edema
Interventions: intravitreous aflibercept, Bevacizumab + Deferred Aflibercept Group; Drug
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 18 Years and older
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 54
States / cities: Campbell, California • Glendale, California • Loma Linda, California + 46 more

Conditions: Cesarean Section Complications
Interventions: Ibuprofen, acetaminophen, oxycodone; Drug
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Asthma
Interventions: GW685698X, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older
Enrollment: 599 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 94
States / cities: Phoenix, Arizona • Fort Smith, Arkansas • Little Rock, Arkansas + 81 more

Conditions: Overactive Bladder
Interventions: Omega 3 Fatty Acid, Placebo; Drug
Lead sponsor: TriHealth Inc.; Other
Eligibility: 18 Years to 85 Years · Female only
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Dyslipidemias, Hyperlipidemias, Hyperlipoproteinemias
Interventions: Vupanorsen, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 40 Years and older
Enrollment: 286 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 59
States / cities: Gilbert, Arizona • Little Rock, Arkansas • Lincoln, California + 35 more

Conditions: Tobacco Use Disorder
Interventions: active repetitive transcranial magnetic stimulation, sham repetitive transcranial magnetic stimulation, cognitive behavioral therapy for smoking cessation, nicotine replacement therapy; Device · Behavioral · Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 75 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Hypertension
Interventions: FAITH! HTN app; Behavioral
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Thyroid Lobectomy
Interventions: Pre-Surgery Survey, Post-Surgery Surveys; Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Chronic Sinusitis
Interventions: IV Acetaminophen, Placebo; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 68 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Sarcoidosis, Precapillary Pulmonary Hypertension, Interstitial Lung Disease
Interventions: Inhaled Treprostinil; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 99 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: COVID-19
Interventions: Placebo for SLV213, SLV213; Other · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Overland Park, Kansas

Search by objective public record fields.

Etomidate Versus Ketamine for Emergency Endotracheal Intubation: a Prospective Randomized Clinical Trial

Efficacy and Safety Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder

AESOPS Trial 2 (AESOPS-2): Availability of Opioid Harm

Bromelain, Comosain as a New Drug for Treating and Preventing Various Types of Cancer in the Humans

Evaluation of the Mobile Acute Care of the Elderly (MACE) Unit

Orexin Antagonism for Suicide Risk: A Proof-of-Concept Clinical Trial

Study to Evaluate the Safety and Efficacy of PEER Interactive Versus Treatment as Usual in Subjects With a Primary Diagnosis of Depression

Comparison of SLx-4090 Combined With Statin Therapy Versus Statin Alone in Reducing LDL-C in Patients With Hyperlipidemia

Study of Recombinant Influenza Vaccine Containing Different H3 Antigens Without or With Adjuvant in Healthy Adult Subjects

A Study of RoActemra/Actemra (Tocilizumab) Given Subcutaneously in Combination With Traditional DMARDs in Patients With Moderate to Severe Active Rheumatoid Arthritis

Exploratory Study Comparing Signs and Symptoms in Patients With Ocular Hypertension or Glaucoma Using Xalatan R® or Travatan Z®

Walking Effect of Long Term Ticagrelor in Subjects With PAD Who Have Undergone EVR

First Line Radiofrequency Ablation Versus Antiarrhythmic Drugs for Persistent Atrial Fibrillation Treatment (RAAFT-3)

DRCR.Net Aflibercept vs. Bevacizumab + Deferred Aflibercept for the Treatment of CI-DME

Towards Enhanced Recovery After Cesarean

A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Asthma Uncontrolled on Non-steroidal Therapy.

Oxybutynin and Omega-3 for OAB (Overactive Bladder)

A Dose-Ranging Study With Vupanorsen (TRANSLATE-TIMI 70)

Neuroimaging Correlates and Feasibility of Transcranial Magnetic Stimulation (TMS) to Improve Smoking Cessation Outcomes in Veterans With Comorbid PTSD

HTN App for HTN Control and Cardiovascular Health Among African-Americans

A Randomized Control Trial for Patient Reported Outcomes and Safety in Outpatient Thyroid Lobectomy

Intraoperative and Post-operative Analgesic Effect of IV Acetaminophen for Sinus Surgery

Inhaled Treprostinil in Sarcoidosis Patients With Pulmonary Hypertension

Safety Study of SLV213 for the Treatment of COVID-19.